# Development of an Integrated Sample Amplification Control for Salivary Point-of-Care Pathogen Testing

- 3
- 4 Navaporn Sritong<sup>1</sup>, Winston Wei Ngo<sup>1</sup>, Karin F. K. Ejendal<sup>1</sup>, Jacqueline C. Linnes<sup>1,2\*</sup>
- 5 1: Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, USA
- 6 2: Department of Public Health, Purdue University, West Lafayette, IN, USA
- 7 \* jlinnes@purdue.edu, +1-765-409-1012
- 8

### 9 Keywords

- 10 Reverse transcription Loop-mediated isothermal amplification, SARS-CoV-2, Diagnostic, Lateral flow
- 11 immunoassay, Internal amplification control, Saliva
- 12
- 13 Abstract

Background: The COVID-19 pandemic has led to a rise in point-of-care (POC) and home-based tests, but concerns over usability, accuracy, and effectiveness have arisen. The incorporation of internal amplification controls (IACs), essential control for translational POC diagnostics, could mitigate false- negative and falsepositive results due to sample matrix interference or inhibition. Although emerging POC nucleic acid amplification tests (NAATs) for detecting SARS-CoV-2 show impressive analytical sensitivity in the lab, the assessment of clinical accuracy with IACs is often overlooked. In some cases, the IACs were run spatially, complicating assay workflow. Therefore, the multiplex assay for pathogen and IAC is needed.

21

22 Results: We developed a one-pot duplex reverse transcriptase loop-mediated isothermal amplification (RT-23 LAMP) assay for saliva samples, a non-invasive and simple collected specimen for POC NAATs. The 24 ORF1ab gene of SARS-CoV-2 was used as a target and a human 18S ribosomal RNA in human saliva was 25 employed as an IAC to ensure clinical reliability of the RT-LAMP assay. The optimized assay could detect 26 SARS-CoV-2 viral particles down to 100 copies/µL of saliva within 30 minutes without RNA extraction. 27 The duplex RT-LAMP for SARS-CoV-2 and IAC is successfully amplified in the same reaction without 28 cross-reactivity. The valid results were easily visualized in triple-line lateral flow immunoassay, in which 29 two lines (flow control and IAC lines) represent valid negative results and three lines (flow control, IAC, 30 and test line) represent valid positive results. This duplex assay demonstrated a clinical sensitivity of 95%, 31 specificity of 100%, and accuracy of 96% in 30 clinical saliva samples.

32

Significance: IACs play a crucial role in ensuring user confidence with respect to the accuracy and
 reliability of at-home and POC molecular diagnostics. We demonstrated the multiplex capability of SARS COV-2 and human18S ribosomal RNA RT-LAMP without complicating assay design. This generic platform
 can be extended in a similar manner to include human18S ribosomal RNA IACs into different clinical
 sample matrices.

- 39
- 40
- 41
- 42
- 43
- 44
- 45 46

#### 47 Introduction

48

49 Due to the COVID-19 pandemic, there has been a rapid increase in the development and availability of 50 point-of-care (POC) and home-based nucleic acid amplification tests (NAATs) for respiratory infections. 51 However, this has also given rise to user concerns regarding the accuracy and effectiveness of these tests 52 and has raised questions about the future of at-home diagnostics for other infectious diseases [1]. Without 53 the same level of quality control and assurance as laboratory-based tests, sample quality and the way it is 54 collected and handled can lead to challenges with accuracy, reliability, and reproducibility [2].

55

56 According to the US FDA guidelines for *in vitro* diagnostic devices, internal analytical controls (IACs) are 57 among the essential controls mandated for the industry [3]. In the lab, an IAC is commonly run in parallel 58 with NAATs in order to rule out a false-negative result [4] and to qualify the sample collection process as 59 well as the integrity of the amplification enzymes and conditions in a presence of complex matrix [5]. An 60 IAC, sometimes referred to as a sample adequacy control, can contain a synthetic target sequence of different length, a non-target sequence, or a housekeeping gene of human cells to ensure sample is 61 62 adequately collected and prepared. IACs are also crucial in POC diagnostics to ensure accurate and reliable 63 detection, particularly when performed at locations with limited access to laboratory facilities [6]. The 64 inclusion of an IAC in POC diagnostics can help to reduce the risk of false-negative results, which can have 65 serious implications for the management of infectious diseases due to delayed or inadequate treatment, 66 potentially resulting in disease transmission, increased morbidity, and mortality [7].

67

68 While many emerging publications on NAATs for SARS-CoV-2 show remarkable analytical sensitivity in 69 the laboratory setting [8], assessing clinical accuracy with IAC is often overlooked. Incorporating an IAC 70 into POC NAATs can present challenges such as requirements of more complex assay design and higher 71 volume of samples to run the control, which subsequently leads to additional user step. Nevertheless, there 72 are some works that have integrated an IAC on their diagnostic assays as shown in Table 1. Reported IACs 73 were performed in separated reactions from tests for the virus, leading additional user steps, increased cost 74 of reagents, and increased risk of contamination between samples [9–15]. In contrast, a one-pot multiplexed 75

reaction can streamline the assay workflow, decrease the required sample volume, and mitigate the likelihood of cross-contamination among reaction zones, leading to enhanced assay efficacy [16]. While details are not stated, some portable and benchtop commercial SARS-CoV-2 molecular diagnostic tests such as ID NOW<sup>TM</sup> COVID-19 2.0, Visby Medical Respiratory Health Test, Aptitude Metrix<sup>TM</sup> COVID-

such as iD NOW in COVID-19 2.0, Visby Medical Respiratory Health Test, Aptitude Metrix COVID-19
19 test, and Cue's COVID-19 Diagnostic Test included IAC in their tests as part of result interpretation
[17].

81

82 Isothermal amplification reactions, such as reverse transcription loop-mediated isothermal amplification 83 (RT-LAMP) for the detection of SARS-CoV-2 have recently been highlighted due to their key features: 84 rapid detection without the need for sophisticated equipment or specialized training [18], reagent 85 accessibility [19], comparable sensitivity and specificity [20]. With 6 separate primers required, 86 multiplexed RT-LAMP are commonly not considered. However, multiple publications have demonstrated 87 that RT-LAMP assays can be multiplexed to detect multiple targets in a single reaction [21–23]. These can 88 be achieved by including multiple primer sets targeting different regions of the target sequence, as well as 89 incorporating separate probes to differentiate the amplified products.

90

91 Choosing an appropriate sample matrix for viral infection diagnosis is essential as it plays a key role in

obtaining reliable diagnostic results. Saliva has been reported as an alternative to nasopharyngeal specimens
 for respiratory virus testing including SARS-CoV-2 [24]. Overall, saliva sampling offers several advantages

94 in terms of simplicity for users. Saliva collection is user-friendly and can be performed without medical

95 personnel, reducing the burden on healthcare professionals. Due to its non-invasive nature, saliva sampling

96 is less intimidating, especially for children and older individuals who may have difficulty with nasal swab

97 collection [25]. Moreover, the time required for specimen collection and the associated cost of using saliva98 are significantly lower compared to using nasopharyngeal specimens [26].

99

Despite being easier to collect, salivary components have been demonstrated to hinder RT-LAMP reactions,

101 posing similar challenges to those observed with nasal swab samples. As a result, false-negative results due

to assay failure could be observed. To improve clinical accuracy and ease of use and avoiding the drawbacks

of a parallel reaction, we have developed a one-pot duplex RT-LAMP assay that uses human 18S ribosomal
 RNA (18S rRNA) as an IAC in human saliva with the ORF1ab gene of SARS-CoV-2 as the target pathogen.
 Our optimized assay can detect SARS-CoV-2 viral particles as low as 100 copies/µL of saliva within 30

minutes. The duplex RT-LAMP for SARS-CoV-2 and IAC can be amplified in one-pot reactions withoutcross-reactivity, and valid results are easily visualized in triple-line lateral flow immunoassays (LFIAs).

108 The appearance of flow control and IAC lines represent valid negative results, and the flow control, IAC, 109 and test lines represent valid positive results. The duplex RT-LAMP assay was validated directly on clinical

- saliva samples without prior RNA extraction. The IAC developed here meet the FDA guidelines for In
- 111 *Vitro* Diagnostic Devices [6] to bring clinically relevant molecular diagnostic into POC settings without
- 112 complicating platform design.
- 113

## **114 2.** Materials and methods

- 115
- 116 2.1 Reagents

117 Reagents for RT-LAMP reactions included WarmStart® Multi-Purpose LAMP/RT-LAMP 2X Master Mix 118 119 with UDG from NEB (Ipswich, MA), EvaGreen from VWR International (Radnor, PA), ROX from Thermo 120 Fisher Scientific (Waltham, MA), and nuclease-free water from Invitrogen (Waltham, MA). Pooled human 121 saliva used in assay development was purchased from Innovative Research (Novi, MI). BtsYI and Ddel 122 restriction enzymes were purchased from NEB (Ipswich, MA). The viral templates obtained from BEI 123 Resources (Manassas, VA) included Heat inactivated Novel Coronavirus, 2019-nCoV/USA-WA1/2020, 124 NR-52286 (SARS-CoV-2); Middle East Respiratory Syndrome Coronavirus (MERS CoV), EMC/2012, 125 Irradiated Infected Cell Lysate, NR-50549; and SARS Coronavirus (SARS), NR-9547; and purified 126 genomic RNA from dengue virus (DENV) type 1. All primers, including those conjugated to FITC, biotin 127 and DIG, were ordered from Integrated DNA Technologies (Coralville, IA).

128

129 2.2 Singleplex RT-LAMP for SARS-CoV-2 detection130

131 The primer set targeting ORF1ab region of SARS-CoV-2 (GenBank: OQ691200.1) was used (Table S1.). 132 The RT-LAMP reactions were carried out by using 2x WarmStart® Multi-Purpose LAMP/RT-LAMP 133 Master Mix in accordance with the New England Biolab standard and 10X Primer Mix containing all 6 134 LAMP primers (final concentration of 1.6 µM for forward inner primer (FIP) and backward inner primer 135 (BIP),  $0.4 \,\mu$ M for forward loop primer (LF) and backward loop primer (LB), and  $0.2 \,\mu$ M for forward outer 136 primer (F3) and backward outer primer (B3). The 5' end of LF and LB were labeled with fluorescein (FITC) 137 or biotin, respectively for LFIA detection. The robustness of primer sets in various saliva percentages (0-138 30%) were evaluated to determine volume of saliva sample used in the assay. Various concentrations of 139 SARS-CoV-2 viral particles were spiked into saliva samples at concentrations ranging from 0 to 5000 140 SARS-CoV-2 viral copies/µL to determine the limit of detection (LOD) of the assay. The saliva without 141 viral particles was used as a no template control (NTC). Five (5)  $\mu$ L of saliva sample and 20  $\mu$ L of 142 mastermix were incubated at 65°C for 30 minutes in a QuantStudio 5 Real-Time PCR machine 143 (ThermoFisher, Waltham, MA). The specificity of optimized RT-LAMP against other coronaviruses was 144 performed by using SARS, MERS CoV, DENV viruses as targets. To validate the amplification process, 145 real-time fluorescence data of EvaGreen intercalating dye and ROX reference dye were recorded. The RT-146 LAMP amplicons were visualized via LFIA and confirmed via gel electrophoresis using a 2% agarose gel

run at 100 V for 50 minutes, stained with ethidium bromide, and imaged using an ultraviolet light gel
imaging system (c400, Azure Biosystems, Dublin, CA).

149

*2.3 Singleplex RT-LAMP for human RNA in saliva for amplification control* 

152 To verify the proper collection of saliva and avoid potential false-negative results due to technical errors, 153 we searched the literature for primer sets targeting ubiquitously expressed genes in human samples. In this 154 work, the primer set targeting human 18S rRNA (GenBank: AL592188.60) developed by Garneret et al 155 [11] was selected (Table S1) since it resulted in consistent results. To confirm that IAC primers are 156 orthogonal to SARS-CoV-2 primers and RNA, in-silico PCR validation was carried out using free software 157 - UCSC In-Silico PCR [27]. The RT-LAMP of IAC was performed as described in singleplex RT-LAMP 158 for SARS-CoV-2 detection experiment. SARS-CoV-2 spiked water, saliva sample, and total human RNA 159 control (Applied Biosystems, Waltham, MA) were used as a template for RT-LAMP of 18S rRNA. The 5' 160 end of LF and LB were tagged with digoxigenin (DIG) and biotin, respectively for LFIA detection. The 161 amplification was confirmed by gel electrophoresis and the LOD was determined via LFIA. In the LOD 162 experiment, the total human RNA control was 10-fold diluted from 4.4 x  $10^6$  copies/ $\mu$ L and used as 163 templates.

164

### 165 2.4 One-pot duplex RT-LAMP of SARS-CoV-2 and human RNA

166

167 The optimized duplex RT-LAMP consisted of the two sets of 10x Primer Mix targeting the ORF1ab gene 168 or 18S rRNA in which concentrations of FIP and BIP from both sets were adjusted to 1.0 µM while the 169 concentrations of F3, B3, LF, and LB from both sets remained the same as in the singleplex RT-LAMP 170 conditions. Templates used in these experiments were one target and two target templates. The one target 171 template included SARS-CoV-2 spiked water and saliva without viral particles, while two target template 172 was SARS-CoV-2 spiked saliva. The nuclease-free water was used as NTC in this experiment. The 173 amplifications of duplex RT-LAMP were visualized on triple-line (FITC, DIG, flow control) LFIA strips. 174 The nuclease-free water was used as the NTC to ensure that there is no contamination or cross-reactivity 175 between two primer sets. To assess the LOD of the duplex RT-LAMP assay, saliva samples were spiked 176 with different concentrations of SARS-CoV-2 viral particles ranging from 0 to 5000 SARS-CoV-2 viral 177 copies/ $\mu$ L. The duplex RT-LAMP reactions were prepared in total volume of 50  $\mu$ L with 5  $\mu$ L of sample 178 and incubated at 65°C for 30 minutes in the QuantStudio5 (Applied biosystems, Waltham, MA).

179

181

180 2.5 Restriction enzyme digestion of duplex RT-LAMP products

182 To validate the expected amplification products, the duplex RT-LAMP products were digested with the 183 restriction enzyme BtsYI and Ddel that are specific to the products of SARS-CoV-2 and IAC primers, 184 respectively. To determine restriction enzymes that specifically cut the product of SARS-CoV-2 or 18S 185 rRNA RT-LAMP, and not both, the NEBcutter software was used [28]. The templates used in this 186 experiment included SARS-CoV-2 spiked water as SARS-CoV-2 primer product, SARS-CoV-2 free-saliva 187 as IAC primer product, and SARS-CoV-2 spiked saliva as duplex product. The reaction consisted of 5  $\mu$ L 188 of amplicons, 2.5 µL CutSmart Buffer (NEB, Ipswich, MA), and 1 µL of restriction enzyme. The nuclease-189 free water was added to fill up reaction volume to 25 µL. The reactions were then incubated at 37°C in 190 water bath for 20-30 minutes. The restriction fragments of duplex RT-LAMP products were visualized 191 using ethidium bromide in a 2% agarose gel.

192

# 193 2.6 Clinical sample validation194

195 The developed assay was validated against frozen clinical saliva samples received from Indiana Biobank 196 (Bloomington, IN). The saliva samples were collected in 2 mL cryovials and stored in -80°C upon arrival 197 in workshop to the saliva samples were collected in 2 mL cryovials and stored in -80°C upon arrival

in our lab. These samples were assigned as study ID 1-30, aliquoted, and used as templates for the standard

198 RT-qPCR and duplex RT-LAMP. Of 30 clinical samples, three (3) SARS-CoV-2 negative samples had 199 insufficient volume to extract RNA and run both RT-qPCR and duplex RT-LAMP. Therefore, additional 3 200 samples were collected from subjects who were negative for COVID-19 by using RNAPro•SAL<sup>™</sup> (Oasis 201 Diagnostics<sup>®</sup>, Vancouver, WA) in accordance with Purdue University IRB protocol # IRB-2020-968. All 202 clinical samples were heat-inactivated at 95°C for 5 minutes to ensure safety of working conditions in a 203 BSL-2 laboratory [29] and stored at  $-80^{\circ}$ C until use. To validate duplex RT-LAMP against clinical samples, 204 5 or 10 µL of heat-inactivated samples were used as templates with 45 or 40 µL of RT-LAMP master mix 205 as described in one-pot duplex RT-LAMP experiment. Each sample was run in triplicate and visualized on 206 trip-line LFIAs. The samples for RT-qPCR were extracted by using the QIAamp Viral RNA Mini Kit 207 (Qiagen, Hilden, Germany) according to manufacturer's protocol. Ten (10) µL of extracted samples was 208 used for RT-qPCR analysis using FDA authorized 2019-nCoV: Real-Time Fluorescent RT-PCR kit (BGI, 209 Shenzhen, China) targeted the ORF1ab gene of SARS-CoV-2 genome and human  $\beta$ -actin gene as the IAC. 210 The RT-qPCR was run twice for each sample. The clinical sensitivity and specificity of duplex RT-LAMP 211 assay were evaluated as followed [30]: Sensitivity = (true positive)/(true positive + false negative);212 Specificity = (true negative)/(true negative + false positive); Accuracy = (true positive + true negative)/(true 213 positive + true negative + false positive + false negative).

214

# 215 2.7 LFIA quantification, statistical analysis, and graphical abstract 216

217 The LFIA tests were run in triplicates for each experiment. The LFIA quantification and statistical analysis 218 were performed as described by Phillips et al [31]. Briefly, after 15 mins of initial sample addition, the 219 LFIAs were scanned using Epson V850 Pro Scanner. A custom MATLAB script was used to quantify the 220 test band, which averages the grey-scale pixel intensity of the test band and subtracts the average 221 background pixel intensity 40 pixels below the test band. The LOD was determined by a one-way ANOVA 222 with Dunnett's post hoc test with multiple comparisons using GraphPad prism (GraphPad Software, Boston, 223 MA) of the LFIA test bands of each concentration against the test bands from negative controls (no 224 template) with a 95% confidence interval. The graphical abstract is created in Biorender (Toronto, Canada).

225

# 226 3. Results and discussion


227

# 3.1 Analytical sensitivity and specificity of SARS-CoV-2 RT-LAMP assay in saliva samples 229

230 Throughout the stages of infection, the viral load can be as low  $10^3$  to  $10^5$  copies/mL of saliva sample 231 (equivalent to 1 to 100 copies/ $\mu$ L of saliva) in early stage and spiked to 10<sup>8</sup> copies/ $\mu$ L (10<sup>5</sup> copies/ $\mu$ L) in 232 later stage [32]. To evaluate the analytical sensitivity of SARS-CoV-2 RT-LAMP assay, saliva spiked with 233 various concentration of inactivated SARS-CoV-2 particles was used as templates. The time to detection 234 of SARS-CoV-2 in the RT-LAMP assay was displayed as the cycle threshold (Ct) value against various 235 concentrations of SARS-CoV-2. The singleplex RT-LAMP targeting ORF1ab gene was able to detect as 236 few as 100 SARS-CoV-2 viral copies/µL saliva in less than 30 minutes (Figure 1A). The SARS-CoV-2 237 RT-LAMP products visualized by gel electrophoresis were in a ladder-like pattern (Figure 1B), indicating 238 the successful production of the different length concatemers. The conjugation of the backward loop primer 239 to biotin and the forward loop primer to FITC allowed the result to be readout on LFIAs. The test line of 240 saliva samples with SARS-CoV-2 concentration of 100, 500, and 5000 viral copies/µL were observed 241 (Figure 1C). The presence of the flow control line in all samples suggested that the flow of samples on 242 LFIAs was effective. The analytical sensitivity or LOD of the assay was determined by quantifying test 243 band intensity of each concentration. The custom MATLAB script calculates the average gray-scale pixel 244 intensity of the test band and then subtracts the average background pixel intensity located 40 pixels below 245 the test band. As shown in Figure 1D, there is a statistically significant difference in test band intensity of 246 RT-LAMP products from 100-5000 viral copies/µL in saliva as compared to no template control when 247 using a one-way ANOVA with Dunnett's post hoc. The analysis of gel electrophoresis and LFIAs suggested 248 that our SARS-CoV-2 RT-LAMP assay exhibit the LOD of 100 viral copies/ $\mu$ L saliva, which is in the range

of clinically relevant LOD [32]. Moreover, the developed RT-LAMP assay was specific to SARS-CoV-2
 RNA and demonstrated no amplified products in the gel nor test band on LFIAs when viral particles from
 MERS, DENV1, or CoV were used as a template (Figure S1). Taken together, the RT-LAMP assay in
 saliva is both sensitive and specific for SARS-coV-2 detection.





**Figure 1.** Analytical sensitivity of SARS-CoV-2 RT-LAMP assay in saliva. Ct value of SARS-CoV-2 RT-LAMP in various concentrations (A). RT-LAMP based detection of inactivated viral particles as visualized on gel electrophoresis (B) LFIA (C), and corresponding test band intensity analysis (D). n = 3; \*\*\*\* indicates *p* value  $\leq 0.0001$ . The ladder-like bands on gel electrophoresis indicating successful amplification.

254


#### 255 *3.2 RT-LAMP of 18S ribosomal RNA IAC specific to human RNA in saliva*

256

257 IACs are one of the required controls according to the US FDA guideline for *in vitro* diagnostic devices for 258 various infectious diseases provided to the industry [3]. Given that saliva is the selected sample matrix for 259 the study, we screened for human genes that are expected to be ubiquitously expressed in human saliva to 260 use as the IAC target. Regardless of the presence of target pathogen, the IAC should be detectable in all samples. Another criterion for IAC in this work is that the IAC primers and target should not cross-react 261 262 with SARS-CoV-2 primers, or the SAR-CoV-2 target. No matches were found when conducting an in-263 silico analysis of PCR using primers designed for the 18S rRNA against the SARS-CoV-2 genome and 264 primers (Figure S2). This result suggested that IAC primers are orthogonal to SARS-CoV-2 primers and 265 RNA. The amplification plot of 18S rRNA RT-LAMP in Figure 2A demonstrates that sigmoidal curve of the fluorescence signal showed up only when the positive control — total human RNA control and saliva 266 267 were used as the templates. The amplicons were subsequently analyzed by the gel electrophoresis. As seen 268 in Figure 2B, the gel image displayed the ladder-like bandings when total human RNA control and saliva 269 were used as templates. In contrast, no products were seen on the gel when the template was SARS-CoV-

270 2 particles without saliva. This result confirms that 18S rRNA primers were specific to human RNA control 271 and saliva sample and there is no cross-reactivity against SARS-CoV-2. Therefore, the primer set targeting 272 human 18S rRNA was chosen and incorporated in duplex RT-LAMP as the IAC. It is worth noting that the 273 amount of human 18S rRNA in human saliva can vary depending on several factors including collection 274 method used and the time of day the sample was collected. We ran the LOD of 18S rRNA RT-LAMP and 275 found that the LOD of the assay was 4,400 copies/µL (Figure S3), which is in the range of reported 276 concentrations of 18S rRNA in human saliva by other groups [33].

277 In addition to SARS-CoV-2, saliva could serve as specimen for other respiratory viruses [34] such 278 as Influenza viruses, Respiratory Syncytial Virus (RSV), Adenovirus, and Rhinovirus and even bacterial 279 pathogens such as Group A streptococci causing strep throat, and Bordetella pertussis causing whooping 280 cough [35]. This study suggests that the 18S rRNA could be a suitable IAC for other diagnostic tests that 281 rely on saliva samples. Moreover, this knowledge could also be similarly employed for integrated IACs in 282 other clinical sample matrixes such as urine, nasal swabs, and blood. Kretschmer-Kazemi Far et al reported 283 that 18S rRNA is the most abundant RNA species in urine samples [36] and Garneret et al. reported the use of 18S rRNA as the IAC for nasal swabs [11]. By performing 18S rRNA RT-LAMP using whole blood 284 285 (five (5)  $\mu$ L of undiluted blood), we also demonstrated that 18S rRNA was detectable in freshly collected 286 blood samples (Figure S4.)



**Figure 2.** Specificity of IAC primer. Amplification plot (A) and gel electrophoresis (B) of human 18S rRNA RT-LAMP using different templates. The ladder-like bands indicating successful amplification are only present when saliva and human RNA were used as templates. N = 2.

288

287

289


290 3.3 Optimization of one-pot duplex RT-LAMP of SARS-CoV-2 and IAC

In general, a one-pot multiplexed reaction can simplify the assay workflow and reduce the amount of sample and reagents required. It can also minimize the risk of cross-contamination between reaction zones and improve the overall assay efficiency. However, a one-pot multiplexed reaction can be more challenging to

optimize, and the different targets may compete for limited resources, such as enzymes or primers [37].

296 Therefore, the choices of primers, concentrations, and assay control template are critical to the optimization 297 process. The duplex RT-LAMP of SARS-CoV-2 and IAC consisting of 2 sets targeting the ORF1ab gene 298 and 18S rRNA was performed in a single tube "one-pot reaction". Different template setups were used to 299 examine the interactions between additional primer sets and their cross-reactivities. The successful amplification of sample containing one target (SARS-CoV-2 spiked water (W+) and saliva without viral 300 301 particles (S-)) and two targets (SARS-CoV-2 spiked saliva (S+) are shown on the amplification plot (Figure 302 3A) and gel electrophoresis (Figure 3B). The NTC showed no banding on the gel, confirming that there 303 was no non-specific amplification or primer-dimers. As seen in Figure 3A, the presence of saliva in SARS-CoV-2 spiked saliva sample (S+) slowed down the amplification of SARS-CoV-2 primers as compared to 304 305 SARS-CoV-2 in water (W+). This is likely due to factors in the complex matrices such as saliva that 306 interfere with the activity of the enzymes, degrade or inhibit the RNA template or primers, or increase the 307 viscosity of the reaction mixture [38]. The delayed amplification is not specific to the multiplex RT-LAMP 308 primer set used here and has been observed before when complex matrices were introduced into LAMP 309 reaction [39]. The amplicons from different conditions were visualized on a gel were added to LFIAs (Figure 3C). Without templates of both primer sets (NTC) on the W- strip, only the flow control line was 310 311 present. As anticipated, the W+ strip showed the flow control and test lines, while the S- strip displayed the flow control and IAC lines (Figure 3C). The amplicons of both primers were present on the S+ strip, 312 313 indicating the successful duplexed RT-LAMP of the target pathogen and IAC in one-pot reaction (n=3). 314 This duplex reaction demonstrates the multiplexing capabilities of 18S rRNA and the ORF1ab gene of 315 SARS-CoV-2 in human saliva in the one-pot reaction platform (Figure 3).





**Figure 3.** One-pot duplex RT- LAMP of SARS-CoV-2 and human 18S rRNA. (A) Amplification plot of duplex RT-LAMP using different templates. (B) Gel electrophoresis and (C) corresponding LFIAs of optimized assay (n=3). Integration of 18S rRNA human sample control into duplex RT-LAMP assay demonstrating differentiation between saliva (with 18S rRNA) and water matrix (without 18S rRNA) and SARS-CoV-2 spiked into each matrix. W- and W+ represent water with and without SARS-CoV-2, respectively. S- and S+ represent saliva sample with and without SARS-CoV-2, respectively. (D)

Restriction enzyme digestion of duplex RT-LAMP of SARS-CoV-2 and human 18S rRNA visualized on the gel. Red boxes indicate BstYI digested amplicon with the characteristic band at 110 bp and blue boxes indicate DdeI digested amplicon the characteristic band at 150 bp. Ø indicate non-digested amplicons.

317

### 3.4 Validation of the duplex RT-LAMP products by restriction enzyme digestion

318 319


320 The amplification products of the two primer sets in the duplex RT-LAMP were also confirmed by 321 restriction enzyme digestion by using two specific restriction enzymes: BtsYI, which targets the product of 322 SARS-CoV-2 primers, and Ddel, which targets the IAC primers (Figure 3D). The digested and non-digested 323 amplicons of SARS-CoV-2, 18S rRNA, and duplex products were shown in Figure 3D. For SARS-CoV-2 324 product (SARS-CoV-2 spiked water), the anticipated 110 bp band was observed after BtsYI digestion as 325 seen in lane 2 on the gel. This band did not show up in non-digested SARS-CoV-2 product in lane 1. In 326 case of 18S rRNA product from saliva without SARS-CoV-2, the characteristic band at approximately 150 327 bp was observed when the amplicons were digested with DdeI as shown in lane 4. In lane 3 of non-digested 328 product, the band at 150 bp was absent. Once the duplex RT-LAMP products from SARS-CoV-2 spiked 329 saliva were digested with BtsYI and DdeI, the characteristic band at 110 bp and 150 bp were visible on the 330 gel in lane 6 and lane 7, respectively, along with smear bands of undigested amplicons. This experiment 331 confirms that the duplex RT-LAMP assay could amplify two targets in the one-pot reaction without cross-332 reactivity.

333

# 334 3.5 Analytical sensitivity of duplex RT-LAMP assay of SARS-CoV-2 and IAC 335

336 The LOD of the duplex RT-LAMP assay was determined by detecting different concentrations of SARS-337 CoV-2 spiked into saliva, as was performed in the singleplex SARS-CoV-2 RT-LAMP assay. As seen in 338 Figure 4A, the IAC line showed up in all samples due to the presence of intact human 18S RNA in saliva. 339 The leftmost strip of no viral particles represented a valid negative result. The strips of concentrations 340 ranging from 100-5000 viral copies/uL demonstrated 3 lines; flow control, IAC, and SARS-CoV-2 test 341 lines. Figure 4B demonstrates that there is a statistically significantly difference in the test band of duplex 342 RT-LAMP products ranging from 100-5000 viral copies/µL compared to no template, as confirmed by a 343 one-way ANOVA with Dunnett's post hoc analysis. As a result, the duplex RT-LAMP exhibited a LOD of 344 100 viral copies/µL saliva comparable to single plex SARS-CoV-2 RT-LAMP. With prior heat-inactivation 345 of saliva samples, we could bring the LOD down to 50 viral copies/ $\mu$ L (Figure S5). Moreover, we found 346 that the IAC line intensity demonstrated a statistically significant decrease as the concentration of SARS-347 CoV-2 in the sample was increased. On the other hand, the SARS-CoV-2 test line intensity increased in a 348 concentration-dependent manner. Importantly, while the IAC line remained visible in all tests, we 349 hypothesize that in cases of exceptionally high viral loads of SARS-CoV-2, the viral target could 350 outcompete the IAC in samples. This would lead to the absence of IAC at excess SARS-CoV-2 351 concentrations. In this case, users would be informed to interpret any result with a SARS-CoV-2 line as a 352 positive result. The LODs of SARS-CoV-2 RT-LAMP assays can vary depending on several factors such 353 as the type of assay used, the quality of the sample, and the target genes selected for amplification. As 354 compared to several studies that have reported LODs of SARS-Cov-2 ranging from 10 to 1000 viral 355 copies/µL [40–43], our duplex RT-LAMP could detect both targets without compromising the sensitivity 356 of SARS-CoV-2 primers.

357



**Figure 4.** Analytical sensitivity of duplex RT-LAMP assay of SARS-CoV-2 and IAC in saliva visualized on (A) LFIA and (B) corresponding test band intensity analysis. n = 3; \*/# indicates *p* value  $\leq 0.05$ ; \*\*/## indicates  $p \leq 0.01$ ; \*\*\*/### indicates *p* value  $\leq 0.001$ ; compared to equivalent bands at 0 viral copies/µL.

358

359 3.6 Clinical sample validation

360

361 Clinical sample validation is crucial for the successful implementation of diagnostic assays into clinical 362 practice. It ensures that the assay is accurate, reliable, and can be used to make informed decisions about patient care. To evaluate clinical performance of our assay, we tested 30 deidentified clinical samples 363 364 received from the Indiana Biobank. Since we intend to implement this assay at point-of-care sites, we 365 bypassed any RNA extraction steps and validated the duplex assay by using non-extracted samples. The 366 duplex RT-LAMP assays were run in triplicates for each sample and the results were interpreted on triple-367 line LFIAs. All LFIA results and quantified test line intensities are shown in Figure S6, Figure S7, and Table S2. We found that the IAC lines were observed in all samples although the IAC lines of non-extracted 368 369 sample ID 10 were faint. Therefore, we ran the assay again with extracted samples and found that the IAC 370 lines showed up clearly from this extracted sample ID 10 (Figure S5.) and Ct value of 22 obtained from 371 RT-PCR indicated very high viral load [44]. Saliva sample ID 19 was highly viscous. Therefore, we diluted 372 this sample with the nuclease-free water in a 1:1 ratio before adding to the reaction. Sample dilution is one 373 of sample preparation methods for diagnostic tests that has been shown to help reduce inhibitory factors 374 and viscosity of sample matrices [42].

375

376 The RT-PCR assay of all 30 extracted samples was analyzed as a reference method. The Ct values were 377 used as a parameter for result interpretation according to manufacture (Table S3). The clinical sensitivity 378 and specificity of the RT-PCR kit were shown in Table 2. The results suggest that our duplex RT-LAMP 379 assay with non-extracted samples correctly identified 20 of the 21 RT-PCR-positive samples and accurately 380 detected all 9 SARS-CoV-2 negative specimens. Only non-extracted sample ID 6 was identified as negative 381 while the RT-PCR identified as positive. Sample ID 6 had an RT-PCR Ct value of 33, which is considered 382 to be a very low viral load [45]. When RNA was extracted from sample ID 6, the RT-LAMP assay correctly 383 identified the sample as positive. In general, the viral load of SARS-CoV-2 in saliva may vary throughout 384 the different stages of infection. The study conducted by Juanola-Falgarona et al. shows that the viral load 385 of SARS-CoV-2 in clinical samples exhibited linear relationship with Ct value. The lowest concentration 386 of 1.00E+02 copies/mL corresponded to Ct value of  $34.9 \pm 3$ , while the highest concentration of 1.00E+06387 corresponded to Ct value of  $23.4 \pm 0.7$  [46].

388

On non-extracted saliva samples, the duplex RT-LAMP achieves 95% clinical sensitivity, 100% clinical
 specificity, and 96% accuracy. These are considered well above the acceptable values according to the US

- 391 Food and Drug Administration (FDA) guidance for SARS-CoV-2 diagnostic tests Emergency Use
- 392 Authorization.

#### 393

Table 2. Calculation of sensitivity and specificity for the Duplex RT-LAMP										
		RT-o	PCR							
		Positive	negative							
Duplex RT-	positive	20 (TP)	0 (FP)							
LAMP	negative	1 (FN)	9 (TN)							
		Sensitivity: 95%	Specificity: 100%							

#### 

TP: True positive, FP: False positive, FN: False negative, TN: True negative

### 394

#### 395 4. Conclusion 396

397 We successfully combined an IAC for clinically valid sample collection and assay function with a test for 398 the SARS-CoV-2 virus from saliva using the one-pot duplex RT-LAMP. The test can detect both the target virus (SARS-CoV-2) and IAC in the same reaction without cross-reactivity. Without requiring RNA 399 400 extraction, the duplex RT-LAMP assay was able to detect SARS-CoV-2 down to 100 copies/µL of saliva 401 within 30 minutes, or 50 copies/µL with an additional heat inactivation step. The developed assay exhibited 402 95% clinical sensitivity and 100% specificity with accuracy of 96% on non-extracted saliva samples 403 without heat inactivation. IACs are integral to ensure the accuracy and reliability and user confidence in 404 molecular diagnostics in order to run them at home and at POC sites with minimally trained users. 405 Additionally, both the specific 18S rRNA IAC and general knowledge of duplex RT-LAMP can be applied 406 in similar manner to incorporate IACs into various other clinical sample matrices including blood, urine, 407 and nasal swabs. This work is a promising step toward an integrated sample-to-answer POC device for 408 respiratory infection detection at home or POC sites.

409

#### 410 **CRediT** authorship contribution statement

- 411
- 412 Navaporn Sritong: Conceptualization, Methodology, Investigation, Validation, Writing - original draft
- Winston Wei Ngo: Methodology, Investigation, 413
- 414 Karin F. K. Ejendal: Methodology, Writing - review & editing.
- 415 Jacqueline C. Linnes: Conceptualization, Writing-review & editing, Supervision, Funding acquisition.

#### 416 417 **Declaration of competing interest**

- 418
- 419 Jacqueline C. Linnes is co-founder of EverTrue LLC, a diagnostics company developing paper-based POC
- 420 NAATs, and co-founder of OmniVis Inc. NAAT company developing POC diagnostics. Navaporn Sritong,
- 421 Winston Wei Ngo, and Karin F. K. Ejendal have declared that they have no competing interests.

#### 422 423 Acknowledgement

- 424
- 425 This study received financial support from the Moore Inventor Fellows Award from the Gordon and Betty
- 426 Moore Foundation Award # 9687 and from NIH National Institute on Drug Abuse award #
- 427 DP2DA051910. We would like to recognize Dr. Mohit Verma, Assistant Professor in Agricultural and
- 428 Biological Engineering, Purdue University, for providing information on SARS-CoV-2 primer sequences.
- 429

#### 430 Appendix A. Supplementary data

- 431 432 **Data availability**
- 433
- 434 No data was used for the research described in the article.
- 435
- 436

#### 437 438 **References**

- 439
- [1] N.V. Tolan, G.L. Horowitz, Clinical Diagnostic Point-of-Care Molecular Assays for SARS-CoV-2,
   Clin. Lab. Med. 42 (2022) 223–236. https://doi.org/10.1016/j.cll.2022.03.002.
- J.L.V. Shaw, Practical challenges related to point of care testing, Pract. Lab. Med. 4 (2016) 22–29.
  https://doi.org/10.1016/j.plabm.2015.12.002.
- 444 [3] Class II Special Controls Guideline: In Vitro Diagnostic Devices for Bacillus spp. Detection, (n.d.).
- [4] K.G. Shah, S. Kumar, P. Yager, Near-digital amplification in paper improves sensitivity and speed in biplexed reactions, Sci. Rep. 12 (2022) 14618. https://doi.org/10.1038/s41598-022-18937-8.
- [5] C. Schrader, A. Schielke, L. Ellerbroek, R. Johne, PCR inhibitors occurrence, properties and removal,
  J. Appl. Microbiol. 113 (2012) 1014–1026. https://doi.org/10.1111/j.1365-2672.2012.05384.x.
- 449 [6] U.S. Department of Health and Human Services, Food and Drug Administration, Class II Special 450 Controls Guideline: Nucleic Acid Amplification Assays for the Detection of Trichomonas vaginalis-451 Guideline Industry Food and Drug Administration for and Staff. n.d. 452 https://fda.report/media/92927/Class-II-Special-Controls-Guideline--Nucleic-Acid-Amplification-453 Assavs-for-the-Detection-of-Trichomonas-vaginalis---Guideline-for-Industry-and-Food-and-Drug-454 Administration-Staff.pdf.
- 455 [7] S. Garg, L. Kim, M. Whitaker, A. O'Halloran, C. Cummings, R. Holstein, M. Prill, S.J. Chai, P.D. 456 Kirley, N.B. Alden, B. Kawasaki, K. Yousev-Hindes, L. Niccolai, E.J. Anderson, K.P. Openo, A. 457 Weigel, M.L. Monroe, P. Ryan, J. Henderson, S. Kim, K. Como-Sabetti, R. Lynfield, D. Sosin, S. 458 Torres, A. Muse, N.M. Bennett, L. Billing, M. Sutton, N. West, W. Schaffner, H.K. Talbot, C. Aquino, 459 A. George, A. Budd, L. Brammer, G. Langley, A.J. Hall, A. Fry, Hospitalization Rates and 460 Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 -461 COVID-NET, 14 States, March 1–30, 2020, MMWR Morb. Mortal. Wkly. Rep. 69 (2020) 458–464. https://doi.org/10.15585/mmwr.mm6915e3. 462
- 463 [8] A.D. Subali, L. Wiyono, Reverse Transcriptase Loop Mediated Isothermal Amplification (RT-LAMP)
  464 for COVID-19 diagnosis: a systematic review and meta-analysis, Pathog. Glob. Health. 115 (n.d.)
  465 281–291. https://doi.org/10.1080/20477724.2021.1933335.
- 466 [9] M.N. Anahtar, G.E.G. McGrath, B.A. Rabe, N.A. Tanner, B.A. White, J.K.M. Lennerz, J.A. Branda,
  467 C.L. Cepko, E.S. Rosenberg, Clinical Assessment and Validation of a Rapid and Sensitive SARS468 CoV-2 Test Using Reverse Transcription Loop-Mediated Isothermal Amplification Without the Need
  469 for RNA Extraction, Open Forum Infect. Dis. 8 (2021) ofaa631. https://doi.org/10.1093/ofid/ofaa631.
- [10]Y. Zhang, G. Ren, J. Buss, A.J. Barry, G.C. Patton, N.A. Tanner, Enhancing colorimetric loopmediated isothermal amplification speed and sensitivity with guanidine chloride, BioTechniques. 69
  (2020) 178–185. https://doi.org/10.2144/btn-2020-0078.
- [11]P. Garneret, E. Coz, E. Martin, J.-C. Manuguerra, E. Brient-Litzler, V. Enouf, D.F.G. Obando, J.-C.
  Olivo-Marin, F. Monti, S. van der Werf, J. Vanhomwegen, P. Tabeling, Performing point-of-care
  molecular testing for SARS-CoV-2 with RNA extraction and isothermal amplification, PLOS ONE.
  16 (2021) e0243712. https://doi.org/10.1371/journal.pone.0243712.
- [12]G. Papadakis, A.K. Pantazis, N. Fikas, S. Chatziioannidou, V. Tsiakalou, K. Michaelidou, V. Pogka,
  M. Megariti, M. Vardaki, K. Giarentis, J. Heaney, E. Nastouli, T. Karamitros, A. Mentis, A.
  Zafiropoulos, G. Sourvinos, S. Agelaki, E. Gizeli, Portable real-time colorimetric LAMP-device for
  rapid quantitative detection of nucleic acids in crude samples, Sci. Rep. 12 (2022) 3775.
  https://doi.org/10.1038/s41598-022-06632-7.
- [13]B.A. Rabe, C. Cepko, SARS-CoV-2 detection using isothermal amplification and a rapid, inexpensive
  protocol for sample inactivation and purification, Proc. Natl. Acad. Sci. 117 (2020) 24450–24458.
  https://doi.org/10.1073/pnas.2011221117.
- 485 [14]O. Yaren, J. McCarter, N. Phadke, K.M. Bradley, B. Overton, Z. Yang, S. Ranade, K. Patil, R. Bangale,
  486 S.A. Benner, Ultra-rapid detection of SARS-CoV-2 in public workspace environments, PLOS ONE.
  487 16 (2021) e0240524. https://doi.org/10.1371/journal.pone.0240524.

- [15] J.P. Broughton, X. Deng, G. Yu, C.L. Fasching, V. Servellita, J. Singh, X. Miao, J.A. Streithorst, A.
  Granados, A. Sotomayor-Gonzalez, K. Zorn, A. Gopez, E. Hsu, W. Gu, S. Miller, C.-Y. Pan, H.
  Guevara, D.A. Wadford, J.S. Chen, C.Y. Chiu, CRISPR–Cas12-based detection of SARS-CoV-2,
  Nat. Biotechnol. 38 (2020) 870–874. https://doi.org/10.1038/s41587-020-0513-4.
- 492 [16]S.H. Lee, Y.H. Baek, Y.-H. Kim, Y.-K. Choi, M.-S. Song, J.-Y. Ahn, One-Pot Reverse Transcriptional
  493 Loop-Mediated Isothermal Amplification (RT-LAMP) for Detecting MERS-CoV, Front. Microbiol.
  494 7 (2016) 2166. https://doi.org/10.3389/fmicb.2016.02166.
- 495 [17]C. for D. and R. Health, In Vitro Diagnostics EUAs Molecular Diagnostic Tests for SARS-CoV-2,
   496 FDA. (2023). https://www.fda.gov/medical-devices/covid-19-emergency-use-authorizations 497 medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2 (accessed June 5,
   498 2023).
- [18]C. Amaral, W. Antunes, E. Moe, A.G. Duarte, L.M.P. Lima, C. Santos, I.L. Gomes, G.S. Afonso, R.
  Vieira, H.S.S. Teles, M.S. Reis, M.A.R. da Silva, A.M. Henriques, M. Fevereiro, M.R. Ventura, M.
  Serrano, C. Pimentel, A molecular test based on RT-LAMP for rapid, sensitive and inexpensive
  colorimetric detection of SARS-CoV-2 in clinical samples, Sci. Rep. 11 (2021) 16430.
  https://doi.org/10.1038/s41598-021-95799-6.
- 504 [19]S.A. El-Kafrawy, M.M. El-Daly, A.M. Hassan, S.M. Harakeh, T.A. Alandijany, E.I. Azhar, Rapid and
  505 Reliable Detection of SARS-CoV-2 Using Direct RT-LAMP, Diagnostics. 12 (2022) 828.
  506 https://doi.org/10.3390/diagnostics12040828.
- 507 [20]M. Inaba, Y. Higashimoto, Y. Toyama, T. Horiguchi, M. Hibino, M. Iwata, K. Imaizumi, Y. Doi,
   508 Diagnostic accuracy of LAMP versus PCR over the course of SARS-CoV-2 infection, Int. J. Infect.
   509 Dis. 107 (2021) 195–200. https://doi.org/10.1016/j.ijid.2021.04.018.
- [21]J.H. Kim, M. Kang, E. Park, D.R. Chung, J. Kim, E.S. Hwang, A Simple and Multiplex Loop-Mediated
  Isothermal Amplification (LAMP) Assay for Rapid Detection of SARS-CoV, Biochip J. 13 (2019)
  341–351. https://doi.org/10.1007/s13206-019-3404-3.
- [22]Y. Shao, S. Zhu, C. Jin, F. Chen, Development of multiplex loop-mediated isothermal amplification RFLP (mLAMP-RFLP) to detect Salmonella spp. and Shigella spp. in milk, Int. J. Food Microbiol.
   148 (2011) 75–79. https://doi.org/10.1016/j.ijfoodmicro.2011.05.004.
- [23]E.C. Kline, N. Panpradist, I.T. Hull, Q. Wang, A.K. Oreskovic, P.D. Han, L.M. Starita, B.R. Lutz, Multiplex Target-Redundant RT-LAMP for Robust Detection of SARS-CoV-2 Using Fluorescent Universal Displacement Probes, Microbiol. Spectr. 10 (2022) e01583-21.
  https://doi.org/10.1128/spectrum.01583-21.
- [24]E. Pasomsub, S.P. Watcharananan, K. Boonyawat, P. Janchompoo, G. Wongtabtim, W. Suksuwan, S.
  Sungkanuparph, A. Phuphuakrat, Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study, Clin. Microbiol. Infect. 27 (2021) 285.e1-285.e4.
  https://doi.org/10.1016/j.cmi.2020.05.001.
- [25]A. Langedijk, O. Allicock, M.V. Wijk, D. Yolda-Carr, D. Weinberger, A. Wyllie, L. Bont, Saliva as
  an alternative to nasopharyngeal swabs for detection of respiratory syncytial virus (RSV) in children,
  Eur. Respir. J. 60 (2022). https://doi.org/10.1183/13993003.congress-2022.4519.
- [26]K.K.W. To, C.C.Y. Yip, C.Y.W. Lai, C.K.H. Wong, D.T.Y. Ho, P.K.P. Pang, A.C.K. Ng, K.-H. Leung,
  R.W.S. Poon, K.-H. Chan, V.C.C. Cheng, I.F.N. Hung, K.-Y. Yuen, Saliva as a diagnostic specimen
  for testing respiratory virus by a point-of-care molecular assay: a diagnostic validity study, Clin.
  Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 25 (2019) 372–378.
  https://doi.org/10.1016/j.cmi.2018.06.009.
- [27]L.R. Nassar, G.P. Barber, A. Benet-Pagès, J. Casper, H. Clawson, M. Diekhans, C. Fischer, J.N.
  Gonzalez, A.S. Hinrichs, B.T. Lee, C.M. Lee, P. Muthuraman, B. Nguy, T. Pereira, P. Nejad, G.
  Perez, B.J. Raney, D. Schmelter, M.L. Speir, B.D. Wick, A.S. Zweig, D. Haussler, R.M. Kuhn, M.
  Haeussler, W.J. Kent, The UCSC Genome Browser database: 2023 update, Nucleic Acids Res. 51
  (2023) D1188–D1195. https://doi.org/10.1093/nar/gkac1072.
- 537 [28]NEBcutter 3.0, (n.d.). https://nc3.neb.com/NEBcutter/ (accessed May 25, 2023).

- [29]C. Batéjat, Q. Grassin, J.-C. Manuguerra, I. Leclercq, Heat inactivation of the severe acute respiratory
  syndrome coronavirus 2, J. Biosaf. Biosecurity. 3 (2021) 1–3.
  https://doi.org/10.1016/j.jobb.2020.12.001.
- [30]R. Parikh, A. Mathai, S. Parikh, G. Chandra Sekhar, R. Thomas, Understanding and using sensitivity,
   specificity and predictive values, Indian J. Ophthalmol. 56 (2008) 45–50.
- 543 [31]E.A. Phillips, Stimuli-Responsive Valving Mechanisms for Paper-Based Diagnostics, thesis, Purdue
   544 University Graduate School, 2020. https://doi.org/10.25394/PGS.11949231.v1.
- [32]E.S. Savela, A. Viloria Winnett, A.E. Romano, M.K. Porter, N. Shelby, R. Akana, J. Ji, M.M. Cooper,
  N.W. Schlenker, J.A. Reyes, A.M. Carter, J.T. Barlow, C. Tognazzini, M. Feaster, Y.-Y. Goh, R.F.
  Ismagilov, Quantitative SARS-CoV-2 Viral-Load Curves in Paired Saliva Samples and Nasal Swabs
  Inform Appropriate Respiratory Sampling Site and Analytical Test Sensitivity Required for Earliest
  Viral Detection, J. Clin. Microbiol. 60 (2022) e0178521. https://doi.org/10.1128/JCM.01785-21.
- [33]P. Ostheim, A. Tichý, I. Sirak, M. Davidkova, M.M. Stastna, G. Kultova, T. Paunesku, G. Woloschak,
  M. Majewski, M. Port, M. Abend, Overcoming challenges in human saliva gene expression measurements, Sci. Rep. 10 (2020) 11147. https://doi.org/10.1038/s41598-020-67825-6.
- [34]K.K. To, L. Lu, C.C. Yip, R.W. Poon, A.M. Fung, A. Cheng, D.H. Lui, D.T. Ho, I.F. Hung, K.-H.
  Chan, K.-Y. Yuen, Additional molecular testing of saliva specimens improves the detection of respiratory viruses, Emerg. Microbes Infect. 6 (2017) e49. https://doi.org/10.1038/emi.2017.35.
- [35]W. Tu, A.M. McManamen, X. Su, I. Jeacopello, M.G. Takezawa, D.L. Hieber, G.W. Hassan, U.N.
  Lee, E.V. Anana, M.P. Locknane, M.W. Stephenson, V.A.M. Shinkawa, E.R. Wald, G.P. DeMuri,
  K.N. Adams, E. Berthier, S. Thongpang, A.B. Theberge, At-Home Saliva Sampling in Healthy Adults
  Using CandyCollect, a Lollipop-Inspired Device, Anal. Chem. 95 (2023) 10211–10220.
  https://doi.org/10.1021/acs.analchem.3c00462.
- [36] R. Kretschmer-Kazemi Far, K. Frank, G. Sczakiel, Sampling, Logistics, and Analytics of Urine for RT qPCR-based Diagnostics, Cancers. 13 (2021) 4381. https://doi.org/10.3390/cancers13174381.
- [37]J. Parker, N. Fowler, M.L. Walmsley, T. Schmidt, J. Scharrer, J. Kowaleski, T. Grimes, S. Hoyos, J.
  Chen, Analytical Sensitivity Comparison between Singleplex Real-Time PCR and a Multiplex PCR
  Platform for Detecting Respiratory Viruses, PLOS ONE. 10 (2015) e0143164.
  https://doi.org/10.1371/journal.pone.0143164.
- [38]Z. Li, J.L. Bruce, B. Cohen, C.V. Cunningham, W.E. Jack, K. Kunin, B.W. Langhorst, J. Miller, R.A. 567 568 Moncion, C.B. Poole, P.K. Premsrirut, G. Ren, R.J. Roberts, N.A. Tanner, Y. Zhang, C.K.S. Carlow, 569 Development and implementation of a simple and rapid extraction-free saliva SARS-CoV-2 RT-570 LAMP workflow for workplace surveillance, PLOS ONE. 17 (2022)e0268692. 571 https://doi.org/10.1371/journal.pone.0268692.
- [39]T.J. Moehling, Portable platforms for molecular-based detection of pathogens in complex sample
   matrices, thesis, Purdue University Graduate School, 2020.
   https://doi.org/10.25394/PGS.12739466.v1.
- [40]R. Lu, X. Wu, Z. Wan, Y. Li, X. Jin, C. Zhang, A Novel Reverse Transcription Loop-Mediated
  Isothermal Amplification Method for Rapid Detection of SARS-CoV-2, Int. J. Mol. Sci. 21 (2020)
  2826. https://doi.org/10.3390/ijms21082826.
- [41]J. Lim, R. Stavins, V. Kindratenko, J. Baek, L. Wang, K. White, J. Kumar, E. Valera, W.P. King, R. Bashir, Microfluidic point-of-care device for detection of early strains and B.1.1.7 variant of SARS-CoV-2 virus, Lab. Chip. 22 (2022) 1297–1309. https://doi.org/10.1039/D2LC00021K.
- [42]J.L. Davidson, J. Wang, M.K. Maruthamuthu, A. Dextre, A. Pascual-Garrigos, S. Mohan, S.V.S.
  Putikam, F.O.I. Osman, D. McChesney, J. Seville, M.S. Verma, A paper-based colorimetric
  molecular test for SARS-CoV-2 in saliva, Biosens. Bioelectron. 9 (2021) 100076.
  https://doi.org/10.1016/j.biosx.2021.100076.
- [43]A.J. Colbert, D.H. Lee, K.N. Clayton, S.T. Wereley, J.C. Linnes, T.L. Kinzer-Ursem, PD-LAMP
  smartphone detection of SARS-CoV-2 on chip, Anal. Chim. Acta. 1203 (2022) 339702.
  https://doi.org/10.1016/j.aca.2022.339702.

- [44]F. Yu, L. Yan, N. Wang, S. Yang, L. Wang, Y. Tang, G. Gao, S. Wang, C. Ma, R. Xie, F. Wang, C.
  Tan, L. Zhu, Y. Guo, F. Zhang, Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 71 (2020) 793–798. https://doi.org/10.1093/cid/ciaa345.
- [45]M. Platten, D. Hoffmann, R. Grosser, F. Wisplinghoff, H. Wisplinghoff, G. Wiesmüller, O. Schildgen,
   V. Schildgen, SARS-CoV-2, CT-Values, and Infectivity—Conclusions to Be Drawn from Side
   Observations, Viruses. 13 (2021) 1459. https://doi.org/10.3390/v13081459.
- [46]M. Juanola-Falgarona, L. Peñarrubia, S. Jiménez-Guzmán, R. Porco, C. Congost-Teixidor, M. VaroVelázquez, S.N. Rao, G. Pueyo, D. Manissero, J. Pareja, Ct values as a diagnostic tool for monitoring
  SARS-CoV-2 viral load using the QIAstat-Dx® Respiratory SARS-CoV-2 Panel, Int. J. Infect. Dis.
  122 (2022) 930–935. https://doi.org/10.1016/j.ijid.2022.07.022.
- 599 [47]B. Bruijns, L. Folkertsma, R. Tiggelaar, FDA authorized molecular point-of-care SARS-CoV-2 tests:
  600 A critical review on principles, systems and clinical performances, Biosens. Bioelectron. 11 (2022)
  601 100158. https://doi.org/10.1016/j.biosx.2022.100158.
- [48]G.-S. Park, K. Ku, S.-H. Baek, S.-J. Kim, S.I. Kim, B.-T. Kim, J.-S. Maeng, Development of Reverse
  Transcription Loop-Mediated Isothermal Amplification Assays Targeting Severe Acute Respiratory
  Syndrome Coronavirus 2 (SARS-CoV-2), J. Mol. Diagn. JMD. 22 (2020) 729–735.
  https://doi.org/10.1016/j.jmoldx.2020.03.006.
- [49]S. Bhadra, T.E. Riedel, S. Lakhotia, N.D. Tran, A.D. Ellington, High-Surety Isothermal Amplification
  and Detection of SARS-CoV-2, mSphere. 6 (2021) e00911-20.
  https://doi.org/10.1128/mSphere.00911-20.
- [50]V.L. Dao Thi, K. Herbst, K. Boerner, M. Meurer, L.P. Kremer, D. Kirrmaier, A. Freistaedter, D.
  Papagiannidis, C. Galmozzi, M.L. Stanifer, S. Boulant, S. Klein, P. Chlanda, D. Khalid, I. Barreto
  Miranda, P. Schnitzler, H.-G. Kräusslich, M. Knop, S. Anders, A colorimetric RT-LAMP assay and
  LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples, Sci. Transl. Med. 12 (2020)
  eabc7075. https://doi.org/10.1126/scitranslmed.abc7075.
- [51]J. Qian, S.A. Boswell, C. Chidley, Z. Lu, M.E. Pettit, B.L. Gaudio, J.M. Fajnzylber, R.T. Ingram, R.H.
  Ward, J.Z. Li, M. Springer, An enhanced isothermal amplification assay for viral detection, Nat. Commun. 11 (2020) 5920. https://doi.org/10.1038/s41467-020-19258-y.
- [52]Y.H. Baek, J. Um, K.J.C. Antigua, J.-H. Park, Y. Kim, S. Oh, Y.-I. Kim, W.-S. Choi, S.G. Kim, J.H.
  Jeong, B.S. Chin, H.D.G. Nicolas, J.-Y. Ahn, K.S. Shin, Y.K. Choi, J.-S. Park, M.-S. Song,
  Development of a reverse transcription-loop-mediated isothermal amplification as a rapid earlydetection method for novel SARS-CoV-2, Emerg. Microbes Infect. 9 (2020) 998–1007.
  https://doi.org/10.1080/22221751.2020.1756698.
- [53]C. Yan, J. Cui, L. Huang, B. Du, L. Chen, G. Xue, S. Li, W. Zhang, L. Zhao, Y. Sun, H. Yao, N. Li,
  H. Zhao, Y. Feng, S. Liu, Q. Zhang, D. Liu, J. Yuan, Rapid and visual detection of 2019 novel
  coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay,
  Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 26 (2020) 773–779.
  https://doi.org/10.1016/j.cmi.2020.04.001.
- [54]T. Zheng, X. Li, Y. Si, M. Wang, Y. Zhou, Y. Yang, N. Liang, B. Ying, P. Wu, Specific lateral flow detection of isothermal nucleic acid amplicons for accurate point-of-care testing, Biosens.
  Bioelectron. 222 (2023) 114989. https://doi.org/10.1016/j.bios.2022.114989.
- [55]C. Zhang, J. Lv, Y. Cao, X. Yao, M. Yin, S. Li, J. Zheng, H. Liu, A triple-target reverse transcription
  loop-mediated isothermal amplification (RT-LAMP) for rapid and accurate detection of SARS-CoV2 virus, Anal. Chim. Acta. 1255 (2023) 341146. https://doi.org/10.1016/j.aca.2023.341146.
- [56]P. Nuchnoi, P. Piromtong, S. Siribal, K. Anansilp, P. Thichanpiang, P.A. Okada, Applicability of a
  colorimetric reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for
  SARS-CoV-2 detection in high exposure risk setting, Int. J. Infect. Dis. 128 (2023) 285–289.
  https://doi.org/10.1016/j.ijid.2023.01.010.
- [57] I. Azmi, M.I. Faizan, R. Kumar, S. Raj Yadav, N. Chaudhary, D. Kumar Singh, R. Butola, A. Ganotra,
  G. Datt Joshi, G. Deep Jhingan, J. Iqbal, M.C. Joshi, T. Ahmad, A Saliva-Based RNA Extraction-

- 639 Free Workflow Integrated With Cas13a for SARS-CoV-2 Detection, Front. Cell. Infect. Microbiol.
- 64011 (2021). https://www.frontiersin.org/articles/10.3389/fcimb.2021.632646 (accessed May 30,6412023).
- [58]S. Wei, H. Suryawanshi, A. Djandji, E. Kohl, S. Morgan, E.A. Hod, S. Whittier, K. Roth, R. Yeh, J.C.
  Alejaldre, E. Fleck, S. Ferrara, D. Hercz, D. Andrews, L. Lee, K.A. Hendershot, J. Goldstein, Y. Suh,
  M. Mansukhani, Z. Williams, Field-deployable, rapid diagnostic testing of saliva for SARS-CoV-2,
  Sci. Rep. 11 (2021) 5448. https://doi.org/10.1038/s41598-021-84792-8.
- 646 [59]M.A. Lalli, J.S. Langmade, X. Chen, C.C. Fronick, C.S. Sawyer, L.C. Burcea, M.N. Wilkinson, R.S. 647 Fulton, M. Heinz, W.J. Buchser, R.D. Head, R.D. Mitra, J. Milbrandt, Rapid and Extraction-Free 648 Detection of SARS-CoV-2 from Saliva by Colorimetric Reverse-Transcription Loop-Mediated 649 Isothermal Amplification. Clin. Chem. 67 (2021)415-424. 650 https://doi.org/10.1093/clinchem/hvaa267.
- [60]Real-time COVID-19 testing | Cue, (n.d.). https://cuehealth.com/products/how-cue-detects-covid-19/
   (accessed September 19, 2023).
- [61]Respiratory Health Test POC rapid PCR device, Visby Med. (n.d.).
   https://www.visbymedical.com/respiratory-health-test/ (accessed September 19, 2023).
- [62]ID NOW COVID-19 2.0, (n.d.). https://www.globalpointofcare.abbott/us/en/product-details/id-now covid-19-us.html (accessed September 19, 2023).
- [63] Aptitude, (n.d.). https://www.aptitudemedical.com/product/metrix-covid-19-test (accessed September
  19, 2023).
- [64]E.A. Phillips, T.J. Moehling, K.F.K. Ejendal, O.S. Hoilett, K.M. Byers, L.A. Basing, L.A. Jankowski,
  J.B. Bennett, L.-K. Lin, L.A. Stanciu, J.C. Linnes, Microfluidic rapid and autonomous analytical
  device (microRAAD) to detect HIV from whole blood samples, Lab. Chip. 19 (2019) 3375–3386.
  https://doi.org/10.1039/C9LC00506D.
- 663

665

#### Table 1. Examples of NAATs for SARS-CoV-2 detection

Target gene	IAC target	Sample matrix	Limit of Detection	Clinical sensitivity (%)	Clinical Specificity (%)	Amplification method	Detection method	Reference
SARS-CoV-2 Nsp3 gene		Synthetic RNA	100 copies/reaction	N/A	N/A	RT-LAMP, WarmStart Colorimetric LAMP 2X Master Mix, Bst 3.0 DNA Polymerase, SuperScript IV Reverse Transcriptase	Leuco crystal violet colorimetric method	Park et al.[48]
SARS-CoV-2 ORF1ab, N genes		Synthetic RNA	10-50 copies/reaction	N/A	N/A	RT-LAMP, WarmStart RTX reverse transcriptase, Bst 2.0 DNA polymerase	LFA (Milenia Biotec)	Bhadra et al.[49]
SARS-CoV-2 N, E ORF1a genes	Beta-actin gene, run separately	Synthetic RNA	1-2 copies/µL in dual primer reaction	N/A	N/A	RT-LAMP, WarmStart Colorimetric RT-LAMP 2X Master Mix	Colorimetric assay	Zhang et al.[10]
SARS-CoV-2 N gene		Nasal swabs	100 copies/reaction	97.5	99.7	RT-LAMP, WarmStart 2X Master Mix	Colorimetric assay	Dao Thi et al.[50]
SARS-CoV-2 N gene		Nasal swabs	118.6 copies/reaction	94	90	RT-LAMP, WarmStart Bst 3.0 DNA Polymerase, WarmStartR RT, Q5 High-Fidelity DNA Polymerase	Colorimetric assay	Lu et al.[40]
SARS-CoV-2 N, S genes		Nasal swabs	5 copies/µL	95.4	84	Enhanced recombinase polymerase amplification (eRPA), RNase H, Superscript IV RT	LFA (Milenia Biotec)	Qian et al. <sup>51</sup>
SARS-CoV-2 N gene		Nasal swabs	100 copies/reaction	100	98.7	RT-LAMP, WarmStart Colorimetric RT-LAMP 2X Master Mix	Colorimetric assay	Baek et al.[52]
SARS-CoV-2 ORF1ab gene		Nasal swabs	20 copies/reaction	100	100	RT-LAMP, Bst DNA polymerase, AMV reverse transcriptase	Colorimetric assay	Yan et al.[53]
SARS-CoV-2 ORF1ab, N genes		Nasal swabs	90 copies/µL	71.4	100	RT-RPA Basic Kit with T7 Exo-assisted PNA recognition of RPA amplicon	LFA	Zheng at al.[54]
SARS-CoV-2 E, M, and N genes		Nasal Swabs	187 copies/reaction	100%	N/A	triple-target RT-LAMP (ttRT-LAMP)	Colorimetric assay	Zhang et al[55].
SARS-CoV-2 RdRp gene	RNAse P gene, run separately	Nasal swabs	1,526.76 copies/mL	91.67%	100%	FastProofTM 30 min-TTR SARS-CoV-2 RT-LAMP Kit	Colorimetric assay	P. Nuchnoi, P. Piromtong, S. Siribal et al.[56]
SARS-CoV-2 N, ORF1a genes	Human actin B gene, run separately	Nasal swabs	25,000 copies/mL	87.5	100	RT-LAMP, WarmStart Colorimetric RT-LAMP 2X Master Mix	Colorimetric assay	Anahtar et al.[9]
SARS-CoV-2 N, E genes	RNAse P gene, run separately	Nasal swabs	10 copies/µL	95	100	RT-LAMP, WarmStart DNA Polymerase, WarmStart RTx Reverse Transcriptase, LbCas12a	LFA (Milenia Biotec, TwistDx)	Broughton et al.[15]
SARS-CoV-2 ORF1ab gene	18S rRNA, run separately	Nasal swabs	1 genome copies /µL with image analysis	N/A	N/A	RT-LAMP, GspSSD 2.0 polymerase, AMV-RT	Intercalating agent SYTO82 (nucleic acid stain)	Garneret et al.[11]
SARS-CoV-2 N, ORF1a genes	RNAse P gene, run separately	Nasal swabs	5 copies /reaction	97.4	100	RT-LAMP, WarmStart, Colorimetric WarmStart 2X Master Mix, Bsm polymerase	Colorimetric assay	Papadakis et al.[12]
SARS-CoV-2 N, S genes	RNAse P gene, run separately	Nasal swabs and saliva	S gene primer: 10 copies/reaction, N gene primer: 25 copies/reaction		oositive samples 6 agreement	RT-LAMP, WarmStart LAMP master mix	End point fluorescence	Yaren et al.[14]
SARS-CoV-2 E/S genes		saliva	200 copies/reaction	98	100	RT-RPA, reverse transcriptase enzyme (EpiScript)	LFA (Milenia Biotec)	Azmi et al.[57]
SARS-CoV-2 N, RdRp, ORFlab genes		Saliva	200 copies /µL saliva	97	100	RT-LAMP, WarmStart DNA Polymerase, WarmStart RTx Reverse Transcriptase	Colorimetric assay	Davidson et al.[42]
SARS-CoV-2 ORF1ab gene		Saliva	1.4 copies/µL	96.7	97.1	HP-LAMP, WarmStart Colorimetric LAMP 2X Master Mix	Colorimetric assay	Wei et al.[58]
SARS-CoV-2 ORF1ab, N genes		Saliva	100-200 copies/reaction	85	100	RT-LAMP, WarmStart Colorimetric LAMP 2X Master Mix	Colorimetric assay	Lalli[59] et al.
SARS-CoV-2 N gene	Proprietary	Nasal swabs	1.3 copies/µL	97.4	99.1	RT-LAMP	Results sent to smartphone through app	Cue's COVID-19 Diagnostic Test[60]
SARS-CoV-2 N, ORF1ab genes	B2M RNA	Nasal Swabs	100 copies/swab	93.2	98.9	PCR	Lateral flow strip on device	Visby Medical Respiratory Health Test[61]
SARS-CoV-2 RdRp Gene	Proprietary	Nasal Swab	500 copies/swab	93.3	98.5	Isothermal nucleic acid amplification technology	Result displayed by instrument	ID NOW™ COVID- 19 2.0[62]
SARS-CoV-2 N, ORF-1 genes	Proprietary	Saliva, nasal swab	Swab: 2000 GE/swab Saliva: 20 GE/µL (GE = genome equivalent)	Swab: 96.7 Saliva:90.3	Swab: 99.0 Saliva: 99.3	Isothermal molecular amplification	Result displayed by device	Aptitude Metrix™ COVID-19 Test[63]
SARS-CoV-2 ORF1a gene	18S rRNA, one- pot duplex	Saliva	100 copies/µL	95	100	RT-LAMP, 2X WarmStart LAMP master mix	LFA (BioUstar)	This work

Table S1.RT-LAMP	primer sets targeting the	18S rRNA (IAC	) and the ORF1ab gene	(SARS-CoV-2 target)

Human 18S rRNA target (GenBank: AL592188.60) Target Size: 225bp							
GTTCAAAGCAGGCCCGAGCCGGCTGGATACCGCAGCTAGGAATAATGGAATAGGACCGCGGTTCTATTTTGTTGGTTTTCGGAACT GAGGCCATGATTAAGAGGGACGGCCGGGGGGCATTCGTATTGCGCCGCTAGAGGTGAAATTCCTTGGACCGGCGCAAGACGGACC AGAGCGAAAGCATTTGCCAAGAATGTTTTCATTAATCAAGAACGAAAGTCGGAGG							
18S_rRNA_F3	GTTCAAAGCAGGCCCGAG						
18S_rRNA_B3	CCTCCGACTTTCGTTCTTGA						
18S_rRNA_FIP	TGGCCTCAGTTCCGAAAACCAA-CCTGGATACCGCAGCTAGG						
18S_rRNA_BIP	GGCATTCGTATTGCGCCGCT-GGCAAATGCTTTCGCTCTG						
18S_rRNA_LF-DigN	/5DigN /AGA ACC GCG GTC CTA TTC CAT TAT T						
18S_rRNA_LB-Biotin	/5-Biosg/ ATT CCT TGG ACC GGC GCA AG						

ORF1ab of SARS-CoV-2 target (GenBank: OQ691200.1) Target Size: 202bp							
TGGACCCCAAAATCAGCGAAATGCACCCCGCATTACGTTTGGTGGACCCTCAGATTCAACTGGCAGTAACCAGAATGGAGAACGC AGTGGGGCTCGATCAAAACAACGTCGGCCCCAAGGTTTACCCAATAATACTGCGTCTTGGTTCACCGCTCTCACTCA							
SARS-CoV-2_F3	TGGACCCCAAAATCAGCG						
SARS-CoV-2_B3	GCCTTGTCCTCGAGGGAAT						
SARS-CoV-2_FIP	CCACTGCGTTCTCCATTCTGGT-AAATGCACCCCGCATTACG						
SARS-CoV-2_BIP	CGCGATCAAAACAACGTCGGCCC-TTGCCATGTTGAGTGAGA						
SARS-CoV-2_LF-FITC	/56-FAM/ GTTGAATCTGAGGGTCCACCA						
SARS-CoV-2_LB-Biotin	/5Biosg/ACCCAATAATACTGCGTCTTGG						

**Table S2.** LFIA analysis of RT-LAMP performed on 30 clinical samples with and without extraction. IAC and test line intensities of each of 3 replicates of RT-LAMP assays are shown. Intensity of greater than 0.02 or greater is considered positive by eye [64]. P represents positive. N represents negative. Sample ID 6 was the only sample that indicated discordant results between extracted and non-extracted samples.


	The presence of IAC and test lines											IAC and te	st line intensi	ities				
	Extracted samples samples					ed			Extracte	d samples					Non-ext	racted sample	es	
Sample	IAC	CoV-2		IAC	CoV-2	۰		IAC			SARS-CoV-2	2		IAC			SARS-CoV	-2
ID	line	line	Resu	It line	line	result	1	2	3	1	2	3	1	2	3	1	2	3
	Y	Y	Р	Y	Y fair	nt P	0.123	0.115	0.108	0.021	0.018	0.017	0.099	0.099	0.087	0.010	0.019	0.016
2	Y	Y	Р	Y	Y	Р	0.097	0.077	0.050	0.078	0.083	0.063	0.123	0.089	0.121	0.036	0.053	0.017
	Y	Y	Р	Y	Y	Р	0.065	0.088	0.084	0.088	0.101	0.065	0.117	0.104	0.145	0.050	0.045	0.027
	Y	Ν	Ν	Y	Ν	Ν	0.110	0.116	0.109	-0.002	-0.002	-0.002	0.084	0.114	0.093	-0.001	-0.003	-0.002
	Y	Y	Р	Y	Y	Р	0.078	0.090	0.072	0.097	0.143	0.109	0.102	0.082	0.066	0.037	0.084	0.082
	Y	Y	Р	Y	Ν	Ν	0.095	0.101	0.144	0.001	0.044	0.002	0.086	0.090	0.096	0.003	0.000	0.004
	Y	Y	Р	Y	Y	Р	0.104	0.070	0.038	0.124	0.101	0.065	0.094	0.083	0.070	0.099	0.086	0.066
	Y	Ν	Ν	Y	Ν	Ν	0.124	0.133	0.114	-0.002	-0.003	-0.001	0.103	0.049	0.097	-0.002	0.002	0.001
	Y	Y	Р	Y Y*	Y	Р	0.113	0.098	0.065	0.062	0.117	0.074	0.075	0.047	0.065	0.079	0.045	0.076
0	Y	Y	Р	faint	Y	Р	0.047	0.047	0.057	0.160	0.104	0.100	0.009	0.007	0.009	0.137	0.101	0.100
1	Y	Ν	Ν	Y	Ν	Ν	0.126	0.115	0.123	0.001	-0.001	0.001	0.080	0.141	0.113	0.000	-0.001	-0.001
2	Y	Y	Р	Y	Y	Р	0.092	0.091	0.101	0.086	0.049	0.070	0.066	0.086	0.085	0.080	0.074	0.055
3	Y	Y	Р	Y	Y	Р	0.067	0.052	0.093	0.095	0.089	0.030	0.113	0.089	0.067	0.022	0.017	0.065
4	Y	Y	Р	Y	Y	Р	0.070	0.046	0.061	0.118	0.078	0.124	0.058	0.064	0.069	0.085	0.097	0.129
5	Y	Y	Р	Y	Y	Р	0.068	0.048	0.072	0.109	0.088	0.107	0.039	0.053	0.049	0.069	0.086	0.127
5	Y	Y	Р	Y	Y	Р	0.066	0.087	0.066	0.109	0.155	0.102	0.056	0.080	0.037	0.088	0.127	0.072
7	Y	Y	Р	Y	Y	Р	0.069	0.066	0.071	0.093	0.119	0.108	0.042	0.053	0.044	0.100	0.132	0.091
8	Y	Y	Р	Y	Y	Р	0.101	0.088	0.095	0.044	0.034	0.028	0.122	0.077	0.122	0.083	0.037	0.068


medRxiv preprint doi: https://doi.org/10.1101/2023.10.03.23296477; this version posted October 3, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

19         Y         Y         P         Y         P         0.052         0.041         0.063         0.087         0.094         0.110         0.129         0.115         0.113         0.037         0.07           20         Y         N         N         Y         N         N         0.100         0.118         0.096         0.000         0.001         0.082         0.123         0.112         -0.003         0.00           21         Y         Y         P         Y         P         0.099         0.089         0.098         0.014         0.016         0.120         0.145         0.128         0.033         0.033           22         Y         N         N         Y         O.075         0.113         0.127         0.000         -0.001         0.000         0.145         0.128         0.033         0.033           22         Y         N         N         Y         O.075         0.113         0.127         0.000         -0.001         0.000         0.137         0.069         0.099         0.001         0.000	
21 Y Y P Y P 0.099 0.089 0.098 0.019 0.014 0.016 0.120 0.145 0.128 0.033 0.03	0.000
	. 0.000
22 Y N N Y N N 0.075 0.113 0.127 0.000 -0.001 0.000 0.137 0.069 0.099 0.001 0.00	8 0.047
	2 0.000
23 Y N N Y N N 0.075 0.107 0.121 -0.001 -0.007 -0.002 0.087 0.101 0.096 -0.001 0.00	-0.002
24 Y Y P Y Y P 0.111 0.129 0.111 0.010 0.019 0.013 0.115 0.123 0.112 0.039 0.03	2 0.026
25 Y Y P Y P 0.061 0.058 0.063 0.098 0.088 0.075 0.074 0.053 0.081 0.095 0.11	7 0.110
26 Y Y P Y Y P 0.081 0.078 0.090 0.078 0.064 0.070 0.131 0.115 0.122 0.062 0.04	6 0.048
27 Y Y P Y Y P 0.079 0.079 0.079 0.124 0.089 0.095 0.085 0.079 0.072 0.081 0.09	2 0.080
28 Y N N Y N N 0.135 0.110 0.115 0.002 0.001 -0.001 0.195 0.126 0.152 -0.004 -0.00	1 -0.001
29 Y N N Y N N 0.119 0.138 0.117 0.000 -0.004 0.000 0.163 0.118 0.143 0.001 0.00	-0.003
<u>30 Y N N Y N N 0.130 0.100 0.123 -0.001 0.000 -0.001 0.148 0.141 0.165 -0.003 0.00</u>	4 0.000

**Table S3**. Ct values of clinical sample ID 1-30. A positive result requires a sigmoidal amplification curve in the FAM channel with a Ct value of  $\leq$ 37, and a sigmoidal amplification curve in the VIC/HEX channel with a Ct value of  $\leq$ 35. A negative result is indicated by the absence of a sigmoidal amplification curve in the FAM channel with a Ct value of "0" or a sigmoidal amplification curve in the VIC/HEX channel with a Ct value of  $\leq$ 35. P represents positive. N represents negative.

			Extracted samples							
Sample ID			GI qPCR		result					
-	-	FAM ct	<u></u>	VIC ct	<u>-</u>					
1	30.372	33.506	21.911	23.348	Р					
2	35.325	35.133	28.100	28.778	Р					
3	24.379	24.372	23.274	24.505	Р					
4	0	0	24.562	24.940	Ν					
5	29.733	30.525	20.450	20.599	Р					
6	33.643	33.833	26.562	26.226	Р					
7	26.822	25.953	25.323	23.809	Р					
8	37.132	37.489	24.375	25.993	Ν					
9	30.965	29.877	22.641	22.267	Р					
10	22.319	22.117	24.264	24.843	Р					
11	0	0	25.485	25.638	Ν					
12	31.001	31.219	22.754	22.738	Р					
13	32.311	25.038	34.340	25.641	Р					
14	27.356	27.021	29.878	29.464	Р					
15	25.753	25.065	24.059	22.999	Р					
16	22.972	23.046	23.004	22.862	Р					
17	23.417	21.674	23.398	21.527	Р					
18	32.618	33.312	30.102	29.607	Р					
19	21.441	21.083	24.302	24.517	Р					
20	0.000	0.000	24.115	24.192	Ν					
21	32.384	32.205	25.081	25.211	Р					
22	0	0	29.103	27.581	Ν					
23	0	0	20.637	24.378	Ν					
24	33.581	35.209	21.984	21.707	Р					
25	26.267	26.419	23.427	23.957	Р					
26	30.643	24.207	32.105	25.253	Р					
27	29.981	30.303	26.780	27.682	Р					
28	0	0	30.147	30.456	Ν					
29	0	0	27.319	25.731	Ν					
30	0	0	32.767	32.927	Ν					









Figure S2. In-silico validation of 18S rRNA primer against SARS-CoV-2 genome.



**Figure S3.** Figure S3. Analytical sensitivity 18S rRNA RT-LAMP assay. The amplification plot of 18S rRNA RT-LAMP using various concentration of human RNA control as templates (A). The corresponding gel electrophoresis analysis of 18S rRNA RT-LAMP amplicons (B). The LOD analysis on LFIA (C). The corresponding test band intensity analysis (D). n = 3; \*\*\*\* indicates  $p \le 0.0001$ .




Figure S4. The usability of 18S rRNA as an IAC in blood sample. N = 2






Figure S5. Analytical sensitivity of SARS-CoV-2 RT-LAMP assay in saliva with prior heat-treatment. RT-LAMP based detection of inactivated viral particles visualized on (A) gel electrophoresis (B) LFIA, and (C) corresponding test band intensity analysis. n = 3; \*\*\*\* indicates  $p \le 0.0001$ .




Figure S6. LFIA strips of extracted clinical samples, with the three lines representing "ctrl", "IAC", and test (from the top)

Sample ID 1	Sample ID 2	Sample ID 3	Sample ID 4	Sample ID 5	Sample ID 6	Sample ID 7	Sample ID 8	Sample ID 9	Sample ID 10
Sample ID 11	Sample ID 12	Sample ID 13	Sample ID 14	Sample ID 15	Sample ID 16	Sample ID 17	Sample ID 18	Sample ID 19	Sample ID 20
Sample ID 21	Sample ID 22	Sample ID 23	Sample ID 24	Sample ID 25	Sample ID 26	Sample ID 27	Sample ID 28	Sample ID 29	Sample ID 30

Figure S7. LFIA strips of non-extracted clinical samples